Dr. Barbara Dalton: Barbara is a General Partner of EuclidSR Partners, L.P., an independent venture capital fund formed in 2000 and supported by independent investors, including GlaxoSmithKline, that is focuses on healthcare, information technology and their convergence. She is responsible for sourcing, evaluating, and developing investments in early stage technology based companies.

Prior to EucildSR Partners, Barbara was President of S.R. One, Limited, the venture capital subsidary of GlaxoSmithKline. Barbara joined S.R. One, Limited in 1993 after 10 years as a research scientist in SmithKline Beecham's Pharmaceuticals Research & Development Division. Her scientific career started at The Medical College of Pennsylvania where she received a Ph.D. in Microbiology and Immunology. Barbara is a past President of the Biotechnology Venture Investors Group and a past director of Alere, Inc, Ciphergen Biosystems, Genset SA., Gryphon Sciences, Inc., Physiome Sciences, Molecular Mining, Inc., and Terragen Discovery.

She is currently a director of Scimagix Inc, San Mateo, CA, Rib-X Pharmaceuticals, Inc. in New Haven CT, and iJET Travel Risk Management in Annapolis, MD. In addition to her portfolio company responsibilities she is on the Board of the Greater Philadelphia Venture Group and the non-profit Institute for the Study of Aging.

Recent Investments: Avalon, Rib-X, Targacept, Fluidigm, KuDOS, Xenogen
____________________________________________________

Jordan Davis: Jordan S. Davis is a Managing Partner of Radius Ventures, a venture capital firm focused on early stage investing in the health and life sciences industry. Prior to Radius, Mr. Davis served as a Managing Director at KBL Healthcare, Inc., where he was also focused on early stage investing across a broad range of health and life sciences companies. Previously, Mr. Davis was primarily engaged in financial advisory and money management having served for five years in the Private Client Services and International Equity divisions of Morgan Stanley & Co., Inc. He was a founder of Cambridge Heart, Inc., a cardiology device company and currently serves on the boards of directors of Coordinated Care Solutions, Inc., Health Language, Inc. and Zettacore, Inc., each portfolio companies of Radius. Mr. Davis earned an M.B.A. from the J.L Kellogg Graduate School of Management at Northwestern University (1986) and a B.A. in Economics from The State University of New York at Binghamton (1983).

Radius Ventures is a venture capital firm focused on early stage companies in the health and life sciences industry. We currently manage two funds with total committed capital of approximately $100 million. We invest up to $5 million per investment with an initial commitment in the range of $500,000 to $3,000,000. Our geographic preference is the East Coast but we will invest in other regions.

Recent Investments: U-Systems,Inc., Conor Medsystems, Inc.
____________________________________________________

Ron Hunt: Ron Hunt joined Sprout in January 1998 and is focused on early to late stage investments in life sciences and health care technologies. Prior to joining Sprout, Ron was a consultant with Coopers & Lybrand Consulting and The Health Care Group for a combined 4 years. His consulting work focused on strategic and operational engagements for clients in the pharmaceutical, medical device, and health care services industries. Prior to entering the consulting field, Ron held a number of sales and marketing positions for a combined 8 years with Johnson & Johnson and SmithKline Beecham Pharmaceuticals. Ron is a graduate of The Wharton School (MBA) and Cornell University (BS).

Ron seats in the board of Corixa Corporation, Lathian Systems, Microban International, Pathology Partners, Phase Forward, Protedyne

Recent Investments: Spiration Inc., Auxilium Pharmaceuticals, Inc., Metabasis Therapeutics, Affymax, Inc., Corixa Corporation.
____________________________________________________

Dr. Lee R. Wrubel: Dr. Wrubel is a founder of Foundation Medical Partners and has served as a General Partner since its inception in 2001. He has eight years of experience in venture capital and has been associated with several public companies, including Pozen, OraPharma and Genvec. Prior to starting Foundation Medical Partners, Dr. Wrubel was an investment professional with Canaan Partners (1995-1998) and at Highland Capital Partners (1998-2000), where he specialized in biotechnology and medical devices. He is currently a board member of CardioMEMS, Vascular Architects and CombinatoRx.

Dr. Wrubel began his business career as a consultant at The Wilkerson Group, a healthcare-focused management consulting company. Dr. Wrubel completed a pediatric internship at the Mount Sinai Medical Center in New York. He holds an A.B. from Lafayette College (1986), an M.D. and Masters in Public Health from Tufts University (1990), and an M.B.A. from Columbia University (1995).

Recent Investments: AtriCure, Inc., CardioNet, Inc., Coapt Systems., CombinatoRx, Inc., Immunicon Corporation, Vascular Architects.
____________________________________________________

Mike Kaswan: Mike is a Director at KBL Healthcare Ventures, which manages a $100 million healthcare-focused venture fund and is based in New York. He joined the firm in 1997 and is an active participant in its management, including sourcing, leading and monitoring several of the firm's investments throughout all sectors of healthcare. He was heavily involved in structuring and raising KBL's first institutional fund and building the core investment and administrative team. In addition, he conceived, wrote the business plan for and is a co-founder of Lumenos, Inc., one of the leaders in the emerging field of consumer driven healthcare and a KBL portfolio company. Previously, Mr. Kaswan served in a variety of operating and financial roles at APM Consulting and GE Capital.

Mike earned an B.S. degree in Finance from the McIntire School of Commerce at the University of Virginia and an M.B.A. with distinction from Harvard Business School.

Recent Investments: Neuronetics (www.neuronetics.com), ISTA Pharmaceuticals (www.istavision.com), Corixa Corporation (www.corixa.com), Achillion Pharmaceuticals (www.achillion.com)
____________________________________________________

Martin Vogelbaum: Martin Vogelbaum is general partner for Apple Tree II (ATP II). Prior to joining Apple Tree, Mr. Vogelbaum was a general partner at Oxford Bioscience Partners, which he joined as an Associate in 1993. While at Oxford, Mr. Vogelbaum was involved in more than 50 portfolio investments, including GeneLogic (GLGC), Exelixis (EXEL), Nuvelo (NUVO), formerly Variagenics, Enanta and MicroMed Technology. Prior to joining Oxford, he held senior executive positions at the public and investor relations firms of Burns McClellan and Hill & Knowlton, where he implemented marketing and investor initiatives for biotechnology and pharmaceutical companies.

Previously, he was a Research Associate in the Bone Marrow Transplantation Unit at Memorial Sloan-Kettering Cancer Center, where he conducted research in the area of graft-vs-host disease. Mr. Vogelbaum currently serves on the boards of Nuvelo and Akceli and is Chairman of ATP II companies, Renegade Therapeutics and Gloucester Pharmaceuticals. Mr. Vogelbaum received his A.B. in biology and history from Columbia University.

Recent Investments: Akceli, Cyrano Sciences, Geneos, Gloucester Pharmaceticals, HeartWare, Lexicon
____________________________________________________

John Delaney: John F. Delaney is a partner in the New York office of Morrison & Foerster, where he serves as Co-Chair of the office's Technology Transactions Practice Group.

Mr. Delaney has concentrated his practice on intellectual property and high-technology matters. He has advised clients ranging from Fortune 500 companies to early-stage "Silicon Alley" start-ups on licensing and liability issues. Mr. Delaney has also counseled clients on copyright and other intellectual property issues in connection with corporate finance transactions and mergers and acquisitions. He has negotiated complex IT outsourcing contracts and service level agreements, Joint Ventures, Web site development and hosting relationships, software and content licenses, Internet co-branding and "private label" agreements, and many other types of technology-related contracts. In addition, Mr. Delaney has substantial experience in advising companies on issues such as privacy, contests and sweepstakes, advertising, digital signatures and electronic contracts, auctions, domain names, copyright and trademark registration, unfair competition, and trade secrets. His clients include companies such as A&E Television Networks, The Harry Fox Agency, Hertz, Miramax Films, Multex, Sumitomo Heavy Industries, Yahoo! and Zomba Records.

Mr. Delaney has also represented clients in a wide range of intellectual property–related disputes. For example, he worked on the team that represented Fujitsu Ltd. in its landmark software copyright arbitration with IBM. He represented Chips and Technologies, Inc. in a series of widely publicized patent infringement and unfair competition actions and in an International Trade Commission investigation concerning memory controller chips used in personal computers. He served on the trial team that successfully defended Acuson Corporation in a patent infringement suit involving Acuson's sophisticated diagnostic ultrasound technology.

Mr. Delaney is a frequent lecturer and author on technology and intellectual property law developments, and has been quoted in publications such as Newsweek, Advertising Age and The Wall Street Journal on emerging intellectual property law and business issues. He has appeared on the cover of the American Lawyer as one of the "lawyers for the new economy" and on the cover of New York Lawyer as one of "fifteen lawyers 40 and under shaping the law for the 21st Century." Crain's New York Business recently included him in its "Technology 100," a list of individuals "likely to shape the direction and growth of New York's economy for years to come."

Born in Anchorage, Alaska, Mr. Delaney received his B.A. degree from the University of Notre Dame in 1986, graduating with honors. In 1989, he received his J.D. from Columbia Law School, where he was an Executive Editor of the Journal of Law and the Arts. Mr. Delaney is a member of both the California Bar and the New York Bar.

____________________________________________________